Adenovirus vector manufacturing platform using CIMmultus™️ QA assures the supply of safe vaccines

Published: 4 October 2021
FastFacts
Hana Jug
Hana Jug
BIA Separations, a Sartorius company
Hana is a Project Manager in process development for viral vectors and vaccines at BIA Separations, a Sartorius company. Hana has outstanding experience in downstream purification and analytics of demanding biologics. She has successfully managed several projects for clients in clinical phases, mainly in the field of gene therapy using adeno-associated virus, and vaccines using the adenovirus platform. She holds a BS in Biology from the University of Ljubljana, Slovenia.

Watch the video or read the poster to learn: 

  • Why downstream processing remains one of the main bottlenecks in adenoviral vector manufacturing 
  • How an adenoviral vector purification platform using CIMmultus QA as the key purification step, secures fast and robust process with better purity 
  • CIMmultus™QA offers high capacity and high yields of adenovirus, results in cost reduction and overcomes raw material supply bottlenecks 

Hana Jug is a Project Manager in process development for viral vectors and vaccines at BIA Separations, a Sartorius company. Hana has outstanding experience in downstream purification and analytics of demanding biologics. She has successfully managed several projects for clients in clinical phases, mainly in the field of gene therapy using adeno-associated virus, and vaccines using the adenovirus platform. She holds a BS in Biology from the University of Ljubljana, Slovenia.

Please note all fields marked with an * are mandatory

View article

Already registered? Login

If you have any problem accessing our content, please email info@insights.bio